Equities researchers at HC Wainwright issued their Q3 2025 EPS estimates for shares of Usio in a report issued on Thursday, ...

Analysts at HC Wainwright boosted their FY2025 earnings estimates for shares of Integra Resources in a report issued on ...

Fintel reports that on March 31, 2025, HC Wainwright & Co. initiated coverage of Virax Biolabs Group (NasdaqCM:VRAX) with a ...

H.C. Wainwright adjusted the firm’s price target on BioLineRx (BLRX) to $26 from $9 and keeps a Buy rating on the shares after making ...

H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $150 from $115 and keeps a Buy rating on the shares after the ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the ...

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps ...

Fintel reports that on March 27, 2025, HC Wainwright & Co. initiated coverage of RenovoRx (NasdaqCM:RNXT) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

In a report released today, Kevin Dede from H.C. Wainwright maintained a Hold rating on Biotricity (BTCY – Research Report). The company’s shares closed last Friday at $0.50.

H.C. Wainwright keeps a Buy rating on Milestone Pharmaceuticals (MIST) after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its ...